Journal of Medical Systems

, Volume 34, Issue 3, pp 379–386 | Cite as

Economic Assessment of Thrombocytopenia: CATCH Registry

  • Eric L. Eisenstein
  • Emily F. Honeycutt
  • Kevin J. Anstrom
  • Richard C. Becker
  • Christopher B. Granger
  • Sunil V. Rao
  • Marc E. Jolicoeur
  • E. Magnus Ohman
  • for the CATCH Investigators
Original Paper

Abstract

Thrombocytopenia is associated with increased patient risk. However, the costs of this complication are not well defined. This study assessed the impact of thrombocytopenia on in-hospital costs using results from CATCH, an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy (≥96 h). Thrombocytopenia was defined as: (group 1) an absolute reduction in platelet count to <150 × 109/L; (group 2) a relative reduction in platelet count of >50% from admission levels; or (group 3) both criteria. We found that the development of thrombocytopenia was associated with significantly higher total in-hospital costs for all groups: (group 1) (difference, $8,222; 95% CI, $5,020–$11,425; P < .001); (group 2) (difference, $15,429; 95% CI, $7,472–$23,385; P < .001); and (group 3) (difference, $27,077; 95% CI, $22,901–$31,252; P < .001). However, in our adjusted model, longer lengths-of-stay and greater use of blood transfusions accounted for most incremental in-hospital cost differences.

Keywords

Heparin Thrombocytopenia Cost of Illness Registry Economic Analysis 

References

  1. 1.
    Berkowitz, S. D., Sane, D. C., Sigmon, K. N., et al., Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J. Am. Coll. Cardiol. 32(2):311–319, 1998. doi:10.1016/S0735-1097(98)00252-6.CrossRefGoogle Scholar
  2. 2.
    Eikelboom, J. W., Anand, S. S., Mehta, S. R., Weitz, J. I., Yi, C., and Yusuf, S., Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. Circulation. 103(5):643–650, 2001.Google Scholar
  3. 3.
    Harrington, R. A., Sane, D. C., Califf, R. M., et al., Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. J. Am. Coll. Cardiol. 23(4):891–898, 1994.CrossRefGoogle Scholar
  4. 4.
    Oliveira, G. B., Crespo, E. M., Becker, R. C., et al., Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch. Intern. Med. 168(1):94–102, 2008. doi:10.1001/archinternmed.2007.65.CrossRefGoogle Scholar
  5. 5.
    Ohman, E. M., Granger, C. B., Rice, L., et al., Identification,diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J. Thromb. Thrombolysis. 19(1):11–19, 2005. doi:10.1007/s11239-005-0850-7.CrossRefGoogle Scholar
  6. 6.
    Warkentin, T. E., and Greinacher, A., Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126(Suppl 3):311S–337S, 2004. doi:10.1378/chest.126.3_suppl.311S.CrossRefGoogle Scholar
  7. 7.
    Eisenstein, E. L., and Mark, D. B., Cost effectiveness of new diagnostic tools and therapies for acute coronary syndromes. In: Topol, E. J. (Ed.), Acute Coronary Syndromes. New York: Marcel Dekker, pp. 723–745, 2004.Google Scholar
  8. 8.
    Eisenstein, E. L., Yusuf, S., Bindal, V., et al., What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. J. Card. Fail. 12(5):336–342, 2006. doi:10.1016/j.cardfail.2006.04.002.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Eric L. Eisenstein
    • 1
    • 3
  • Emily F. Honeycutt
    • 2
  • Kevin J. Anstrom
    • 1
  • Richard C. Becker
    • 2
  • Christopher B. Granger
    • 2
  • Sunil V. Rao
    • 2
  • Marc E. Jolicoeur
    • 2
  • E. Magnus Ohman
    • 2
  • for the CATCH Investigators
  1. 1.The Outcomes Research and Assessment Group, Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  2. 2.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA
  3. 3.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations